Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
brimonidine/timolol fixed combination · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| brimonidine/timolol fixed combination | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes * Patient requires IOP-lowering drug in both eyes Exclusion Criteria: * Uncontrolled medical conditions * contraindication to beta-adrenoceptor antagonist or brimonidine therapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
Brimonidine is an investigational small molecule being studied for use in glaucoma, open-angle glaucoma, ocular hypertension, and rhegmatogenous macula-off retinal detachment. It is being developed by AbbVie Inc. (ABBV) for these ophthalmology indications.
Brimonidine is an alpha-2 adrenergic receptor agonist. It works by reducing the production of aqueous humor in the eye, which helps lower intraocular pressure in conditions like glaucoma and ocular hypertension.
Brimonidine is being developed by AbbVie Inc., which trades under the ticker ABBV. The company is conducting clinical trials to evaluate the drug for ophthalmology indications including glaucoma and ocular hypertension.
Brimonidine is in Phase 2 clinical development for rhegmatogenous macula-off retinal detachment. It has completed Phase 3 trials for glaucoma and ocular hypertension, but it remains investigational and is not yet approved by the FDA.
Brimonidine has been studied in several completed trials. NCT00168363 and NCT00652483 evaluated its safety and efficacy in glaucoma and ocular hypertension. NCT00652106 tested a brimonidine/timolol fixed combination. NCT00972374 assessed a posterior segment drug delivery system for retinal detachment.
Brimonidine is the active ingredient in Alphagan, a brand name for the drug. The clinical trials listed under Brimonidine test the same active compound, sometimes in combination with other agents like timolol.